Stock Events

Stock Events

X4 Pharmaceuticals 

$4.08
69
-$0.33-7.48% 15:20 Today

Statistics

Day High
4.48
Day Low
4.08
52W High
4.83
52W Low
1.35
Volume
5,079,794
Avg. Volume
-
Mkt Cap
384.82M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-3.94
-2.48
-1.01
0.45
Expected EPS
-0.176
Actual EPS
N/A

Financials

-1,464.61%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
5.11MRevenue
-74.9MNet Income

Analyst Ratings

11.67Average Price Target
The highest estimate is 12.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XFOR. It's not an investment recommendation.
NVIDIA
10
NVDA
Apple
9
AAPL
Tesla
9
TSLA
Amazon
9
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to X4 Pharmaceuticals' focus on rare diseases.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences competes in the biopharmaceutical space, particularly in areas like HIV and liver diseases, which may overlap with X4 Pharmaceuticals' therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is involved in developing drugs for a variety of diseases, including rare genetic conditions, making it a competitor to X4 Pharmaceuticals.
Biogen
BIIB
Mkt Cap29.4B
Biogen competes with X4 Pharmaceuticals in the area of neurological diseases and has a focus on innovative therapies, potentially overlapping in treatment approaches.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics, including treatments for serious illnesses, which could compete with X4 Pharmaceuticals' rare disease treatments.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation works on small molecule drugs for oncology and inflammation, areas that may intersect with X4 Pharmaceuticals' research interests.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, directly competing with X4 Pharmaceuticals' rare disease portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, making it a direct competitor to X4 Pharmaceuticals.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is engaged in gene editing technologies, which could offer treatments for the same rare diseases targeted by X4 Pharmaceuticals.

About

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Show more...
CEO
Dr. Adam R. Craig M.B.A., M.D., Ph.D.
Employees
143
Country
United States
ISIN
US98420X2027

Listings

F
DE
48Q0.F
MU
DE
48Q.MU
STU
DE
48Q0.STU
MU
DE
48Q0.MU

0 Comments

Share your thoughts

FAQ

What is X4 Pharmaceuticals stock price today?▼
The current price of XFOR is $4.08 USD — it has decreased by -7.48% in the past 24 hours. Watch X4 Pharmaceuticals stock price performance more closely on the chart.
What is X4 Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange X4 Pharmaceuticals stocks are traded under the ticker XFOR.
Is X4 Pharmaceuticals stock price growing?▼
XFOR stock has risen by +2.61% compared to the previous week, the month change is a +3.37% rise, over the last year X4 Pharmaceuticals has showed a +189.16% increase.
What is X4 Pharmaceuticals market cap?▼
Today X4 Pharmaceuticals has the market capitalization of 384.82M
When is the next X4 Pharmaceuticals earnings date?▼
X4 Pharmaceuticals is going to release the next earnings report on August 06, 2026.
What were X4 Pharmaceuticals earnings last quarter?▼
XFOR earnings for the last quarter are -0.16 USD per share, whereas the estimation was -0.2 USD resulting in a +20% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is X4 Pharmaceuticals revenue for the last year?▼
X4 Pharmaceuticals revenue for the last year amounts to 5.11M USD.
What is X4 Pharmaceuticals net income for the last year?▼
XFOR net income for the last year is -74.9M USD.
How many employees does X4 Pharmaceuticals have?▼
As of July 13, 2026, the company has 143 employees.
In which sector is X4 Pharmaceuticals located?▼
X4 Pharmaceuticals operates in the Health & Wellness sector.
When did X4 Pharmaceuticals complete a stock split?▼
The last stock split for X4 Pharmaceuticals was on April 28, 2025 with a ratio of 1:30.
Where is X4 Pharmaceuticals headquartered?▼
X4 Pharmaceuticals is headquartered in Boston, United States.